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Abstract
Background: In this study, we provide a short analytical 
evaluation of the new Fujirebio Lumipulse®G non-com-
petitive immunoassay for 25(OH)D. Clinical performance 
was compared with three commercial competitive auto-
mated immunoassays against a Vitamin D Standardiza-
tion Program (VDSP)-traceable liquid chromatography-
tandem mass spectrometry (LC-MS/MS) in six different 
clinically relevant populations.
Methods: Lumipulse®G 25(OH)D precision, measure-
ment uncertainty, recovery, limit of quantification were 
assessed, as well as 25(OH)D2 and C3-epimer recovery. 
For method comparison, 250 serum samples obtained in 
healthy Caucasians and Africans, osteoporotic, hemodia-
lyzed and intensive care patients and 3rd trimester preg-
nant women were analyzed by all methods. Correlation 
was studied using Passing-Bablok and Bland-Altman 
analysis. Concordance correlation coefficient (CCC) was 
calculated to evaluate agreement between immunoassays 
and the LC-MS/MS.
Results: The Lumipulse®G 25(OH)D assay presented inter-
esting analytical features and showed excellent correla-
tion to the LC-MS/MS results (y = 1.00 × –1.35 ng/mL), as 
obtained in healthy Caucasian individuals. In the other 
special populations, Lumipulse®G presented a concord-
ance with LC-MS/MS which was generally higher than 
competitors, even if all methods significantly under-
recovered 25(OH)D in hemodialyzed patients. Intra-assay 
CV ranged from 12.1% at 9.6 ng/mL to 2.1% at 103.7 ng/mL 
and inter-assay CV ranged from 16.2 to 3.7% at the same 
concentrations, respectively. Measurement uncertainty, 
with a probability of 95%, were respectively 33.1 and 7.6% 
at these concentrations. LOQ was found to be at 4.6 ng/
mL. Mean (95% CI) 25(OH)D2 revovery was 77% (74–81) 
and no cross-reactivity was observed with C3-epimer.
Conclusions: Fujirebio Lumipulse®G 25-OH Vitamin D 
Total assay is therefore considered suitable for assessment 
of vitamin D status in clinical routine.
Keywords: assay performance; concordance; immunoas-
say; LC-MS/MS; vitamin D.
Introduction
The analytical determination of 25-hydroxyvitamin D 
(25(OH)D) is far from an easy task [1, 2]. Indeed, several 
important problems have to be overcome to correctly assess 
this variable. Among them, the very high lipophilic nature 
of the molecule and its strong association with vitamin D 
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binding protein (VDBP) necessitates a thorough separation 
step and, for the one-phase immunoassays, a good equilib-
rium between the analyte and the antibodies used in the 
kits [3]. VDBP can be present at different concentrations 
according to some physiological or pathological condi-
tions, like race [4], pregnancy or chronic kidney disease 
[5–7], which could influence the dissociation kinetics of 
the molecule. Vitamin D can be found as vitamin D2 or D3 
and the assay should ideally measure equally 25(OH)D2 
and 25(OH)D3 [8]. Different other metabolites of vitamin D, 
such as C3-epimer or 24,25(OH)2-vitamin D can be present 
in patients’ serum at different concentrations, possibly 
interfering with immunoassays or liquid chromatography-
tandem mass spectrometry (LC-MS/MS) methods [9]. As 
any other immunoassays, vitamin D assays are prone to 
heterophilic antibodies interference, leading to potential 
spurious results [10]. Last but not least, the standardiza-
tion of the different assays remains a major problem. Hope-
fully, we have now a commonly accepted reference method 
and an ongoing worldwide standardization program, the 
Vitamin D Standardization Program (VDSP) coordinated 
by the CDC, the NIST and the University of Ghent [11]. These 
efforts have globally improved the global concordance of 
different assays for 25(OH)D determination in the “normal 
healthy” population, but some issues are still remaining, 
notably in “special” populations, such as pregnant women 
and African (or Asian) subjects because of their, respec-
tively high and low concentrations of VDBP [7].
Due to potential actions of vitamin D on different dis-
eases [12], the number of 25(OH)D determinations has dra-
matically increased over the last 10 years. This increasing 
number of requests have led most of the clinical laborato-
ries to move from the DiaSorin RIA, the most widely used 
method in the 1990s and early 2000s, to methods present-
ing a larger throughput, i.e. automated immunoassays or 
liquid chromatographs coupled with two mass spectrom-
eters in tandem (LC-MS/MS). All immunoassays were yet 
designed as competitive methods. Very recently, Fujirebio 
(Tokyo, Japan) was the first company to launch on the 
Lumipulse®G instrument a non-competitive (sandwich) 
method for 25(OH)D determination based on antimetatype 
monoclonal antibodies against a hapten-antibody immu-
nocomplex using an ex vivo antibody development system, 
namely the Autonomously Diversifying Library system, a 
process which has recently been validated [13]. The aim 
of this study is first to provide a short analytical evalua-
tion of the new sandwich immunoassay for 25(OH)D and 
also to compare the results obtained with this method and 
three other commercial competitive automated immuno-




Assay precision was determined across the dynamic range using 
serum samples according to a modified version from CLSI protocol 
EP05-A2 [14]. Six human serums were run in duplicate, in the morn-
ing and in the afternoon, for 5 days (n = 20 per sample). The “true” 
value of each of these samples was determined with our VDSP-trace-
able LC-MS/MS (see [7] for details of the LC-MS/MS method), which 
allowed to calculate the measurement uncertainty, as requested by 
the ISO 15189, on two different lots. Variability was expressed in 
standard deviation (SD) and percent coefficient of variation (CV). 
Recovery was obtained by mixing three different high and low level 
samples ¾; ¼, ½; ½ and ¼; ¾ dilutions. Limit of quantification 
(LOQ) was obtained from six samples with low values, run in dupli-
cate, in the morning and in the afternoon, for 5 days. Two different 
lots (5045 and 5066) were used for the evaluation, except for the LOQ, 
for which lot 5117 was used .
The 25(OH)D2 recovery was obtained with 20 native samples 
containing high 25(OH)D2 concentrations according to the method 
we previously published [8]. We also used the same method to cal-
culate the percentage of cross-reactivity with the C3-epimer in 20 
vitamin D3 supplemented subjects presenting high 25(OH)D values 
which were thus prone to present detectable C3-epimer concentra-
tions by LC-MS/MS.
Clinical validation
As all the results were compared to our VDSP traceable LC-MS/MS, 
we confirmed the accuracy of this method with the Labquality panel. 
Next to LC-MS/MS, Lumipulse®G 25(OH)D was also compared to three 
commercial immunoassays for 25(OH)D, namely DiaSorin Liaison XL 
(lot 13181), IDS iSYS (lot 2175) and Roche Elecsys (lot 00180293). For 
this latter method, values  > 70 ng/mL were censored and could not 
thus be used for comparison purposes.
The first comparison was achieved in 100 young healthy sub-
jects spanning the measuring range that had been included in a 
supplementation trial. The second comparison was performed with 
samples obtained from 30 women referred to a specialized osteopo-
rosis clinic. We also compared the methods in populations who are 
known to present different VDBP concentrations: the first one was 
3rd trimester pregnant women (n = 30; high VDBP values) and the 
second one was African healthy subjects from the area of Abidjan, 
Côte d’Ivoire (n = 30; low VDBP values). We also compared the meth-
ods in a population of 30 stable hemodialyzed (HD) patients and 
in 30 patients from the general intensive care unit of our hospital. 
Indeed, these subjects can have a serum matrix which is very differ-
ent from healthy individuals due to nitrogen products accumulation 
or proteins carbamylation or fluid shifts [5–7, 15]. Finally, we com-
pared the assays in subjects presenting high C3-epimer concentra-
tions and endogenous high 25(OH)D2 levels, as determined by our 
LC-MS/MS.
All the samples used in this study were leftover samples kept at 
–80 °C that underwent one cycle of freeze/thawing, which does not 
alter 25(OH)D values [16]. All the comparisons have been performed 
in parallel on all the instruments by our experienced R&D team, in 
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our ISO 15189 accreditated laboratory. The Ethics Committee of the 
CHU de Liege has been informed of the study and has accepted its 
modality.
MedCalc software (Oostende, Belgium) was used for the sta-
tistical comparisons and allowed to perform the Passing-Bablock 
regressions and concordance correlation coefficient (CCC). The CCC 
evaluates the degree to which pairs of observations fall on the 45° 
line through the origin [17]. It contains a measurement of precision 
“r” and accuracy Cb and is calculated as CCC = r Cb, where r is the 
Pearson correlation coefficient (which measures how far each obser-
vation deviates from the best-fit line and thus the precision), and 
Cb is a bias correction factor that measures how far the best-fit line 
deviates from the 45° line through the origin, and is thus a measure 
of accuracy. CCC result can be interpreted as follows: poor ( < 0.90), 
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Figure 1: Bland-Altman plot of Fujirebio Lumipulse (A), DiaSorin Liaison (B), IDS iSYS (1C) and Roche Elecsys (D) against a VDSP-traceable 
LC-MS/MS method in healthy Caucasian subjects, osteoporotic patients, third trimester pregnant women, healthy African subjects, hemo-
dialyzed and intensive care patients.
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Results
Analytical validation of the Lumipulse®G 
25(OH)D assay
The intra-assay CV ranged from 12.1% at 9.6 ng/mL to 
2.1% at 103.7 ng/mL and the inter-assay CV ranged from 
16.2 to 3.7% at the same concentrations, respectively. 
The measurement uncertainty, with a probability of 95% 
ranged from 33.1 to 7.6% for these two concentrations. In 
other words, with an uncertainty of 33.1%, there is 95% of 
chance that the “true” value of i.e. sample 1, which pre-
sents a value of 9.6 ng/mL with our reference method, is 
comprised between 6.4 and 12.8 ng/mL. The mean recovery 
was 101.2±2.4%. The LOQ was found to be at 4.6 ng/mL.
The samples obtained in healthy subjects supple-
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Figure 1: (continued)
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of 25(OH)D3 of 14.0±6.8 ng/mL (range: 6.3–29.5 ng/mL) 
and a mean 25(OH)D2 concentration of 52.8±15.8 ng/mL 
(range: 18.6–80.1 ng/mL) as determined by the LC-MS/MS. 
The mean (95% CI) 25(OH)D2 revovery was 77% (74–81) for 
Fujirebio Lumipulse®G, 89% (82–96) for DiaSorin Liaison, 
86% (80–92) for IDS iSYS and 61% (56–66) for Roche 
Elecsys.
The mean 25(OH)D values observed in the vitamin D3 
supplemented subjects selected to study the C3-epimer 
cross-reactivity was 58.9±14.9 ng/mL (range: 32.1–90.1 
ng/mL). The mean concentration of C3-epimer as measure 
by LC-MS/MS was 7.5±9.6 ng/mL (range: 3.1–47.4 ng/mL). 
None of the immunoassays tested in this study presented 
a significant cross-reactivity with the C3-epimer as the 
95% confidence interval of the mean of cross-reactivity 
encompassed the zero value.
Clinical validation of the Lumipulse®G 
25(OH)D assay
On the Labquality panel, the regression equation we 
obtained for our LC-MS/MS method was Reference 
method = –1.37+1.05 Liege LC-MS/MS. This slope of 1.05 is in 
accordance with the VDSP recommendations that accept 
a bias of ±5% [19]. The Bland-Altman plots of the different 
immunoassays and the LC-MS/MS are presented in Figure 1. 
The Passing-Bablock slopes and intercepts, as well as the 
CCC and quality of the agreement between immunoassays 
and LC-MS/MS, for the global population, but also for all 
the sub-populations are presented in Table 1. To summarize, 
the agreement was substantial with Lumipulse®G, moderate 
with Liaison and poor with iSYS and Elecsys on the overall 
population (n = 250). This agreement was much better in 
the healthy population (substantial/substantial/moderate/
poor for Lumipulse, Liaison, iSYS and Elecsys, respectively) 
compared to the subpopulations. Indeed, the agreement 
was poor for four methods in osteoporotic patients and 
healthy Africans, moderate for Lumipulse but poor for the 
three other immunoassays in hemodialyzed patients, poor 
for Liaison and iSYS but moderate for Lumipulse and sub-
stantial for Elecsys in pregnant women and was substan-
tial for Lumipulse, moderate for Liaison and poor for both 
iSYS and Elecsys for intensive care patients.
Discussion
In this study, we validated the new Fujirebio Lumipulse®G 
25(OH)D assay, which is the first non-competitive method for 
25(OH)D determination. This method presents interesting 
analytical features, even if the CV in the lower range could 
be improved. The limit of quantification at 4.6 ng/mL is 
however, acceptable for clinical purposes. The Fujirebio 
Lumipulse®G assay partially recognizes the 25(OH)D2 form 
and this could be a limitation for the accurate follow-up of 
subjects supplemented with vitamin D2. This study does 
not totally confirm the results we obtained in a previous 
study [20] as none of the assays encompass the 100%. If we 
remain close to 100% for DiaSorin Liaison and IDS iSYS, 
the cross-reactivity for Roche Elecsys that we found here 
was much lower than previously shown. There are multiple 
reasons that could explain this discrepancy. The first one 
could be the concentrations observed in this study vs. the 
previous one. Indeed, we have here much higher 25(OH)D2 
(mean: 52.8 ng/mL) and much lower 25(OH)D3 (14.0 ng/mL) 
than in the other study (means of 40.3 ng/mL for 25(OH)
D3 and 14.3 ng/mL for 25(OH)D2). Another explanation may 
also be the huge difference between the Passing-Bablock 
equation observed between the LC-MS/MS and the Roche 
Elecsys assay in the healthy patients of this study for 25(OH)
D3 (Roche Elecsys = 1.23 × LC-MS/MS–3.35) and the one we 
observed in a comparable healthy population in our previ-
ous study (Roche Elecsys = 0.80 × LC-MS/MS+3.41) whereas 
the other assays tested in both studies present similar equa-
tions. It is not clear why we observed such discrepancies 
for this assay, but there was no reason to reject the series 
performed on Elecsys as the internal QC fitted perfectly in 
the range and the instrument is handled and maintained 
according to the manufacturer’s specifications. In any case, 
these results warrant further investigation.
We also confirmed in this study that the immunoassays 
(at least those that have been tested here) do not cross-react 
with the C3-epimer form. This is also the case for the Roche 
Elecsys assay and we confirm here the results obtained by 
van den Ouweland et al. on native samples [21].
One of the major findings in this paper is that, if there 
is a relatively good concordance between the assays in the 
overall and in the healthy population, this is absolutely 
not the case anymore if we look closely at the subgroups. 
Even if the problem had already been evoked by differ-
ent authors in hemodialyzed and pregnant patients [5, 6], 
this is the first study, to the best of our knowledge, that 
also describes this problem to other subpopulations of 
diseased or healthy African subjects in which the sample 
matrix and/or VDBP polymorphism and concentration 
may differ from healthy Caucasians. On top of that, these 
results may suggest that, during the life of a kit on the 
market, different things can happen (like changes in the 
process, new suppliers, etc.) that affect the diseased, but 
not the healthy population. Clinical chemists must be 
aware that some minor changes that might not have any 
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impact on the healthy population or internal QC can dra-
matically affect different categories of patients.
Osteoporotic women are probably the patients for 
whom vitamin D supplementation and 25(OH)D monitor-
ing is the most relevant. Unfortunately, all the immuno-
assays tested here present a poor concordance with our 
LC-MS/MS. Yet, this population is not homogenous and 
the samples have been selected according to the fact that 
patients had undergone a blood sampling in the frame of 
a specialized osteoporosis consultation. These subjects 
are mainly post-menopausal women treated (or not) for 
osteoporosis but cannot be considered sensu strictu as 
“healthy”. We have unfortunately no clear explanation 
for these observed discrepancies and this deserves further 
investigations. As already mentioned, previous authors 
had already shown important discrepancies when 25(OH)
D was measured by immunoassays or LC-MS/MS in third 
trimester pregnant women or hemodialyzed patients 
[5, 6]. The immunoassays tested here differ from those pre-
viously tested but the conclusion remains the same: they 
remain very inaccurate in these patients and a thorough 
improvement is mandatory. Indeed, this lack of precision 
can have clinical consequences in the sense that under-
ecovery of some immunoassays may lead clinicians to 
increase the supplementation doses to reach a target of 30 
ng/mL. As higher doses of vitamin D can potentially have 
toxic effects [22, 23] this is not free from consequences. We 
also observed an under-recovery in healthy Black African 
subjects, probably depending on the lower concentrations 
of VDBP of these patients, compared to Caucasians [4] and 
the immunoassays tested here and in another study [24] 
are poorly in agreement with the LC-MS/MS for this popu-
lation. Recent papers have shown that the “bioavailable” 
vitamin D [i.e. the free 25(OH)D and the 25(OH)D bound to 
albumin] was probably a better indicator of the vitamin D 
status for Black Americans and have led researchers to 
revisit the free-vitamin D hormone hypothesis [25], even if 
this concept is far from being new [26, 27].
The only “special” population that provided accept-
able results was the patients from the general intensive 
care units. We had previously shown that immunoassays 
were inaccurate in severe burn patients [15], but this was 
not specially the case here. The explanation may be due to 
the fact that the patients of this study were chosen among 
the general ICU ward, and not the burn unit. It is not 
clear however, why the results observed in ICU patients 
are more in agreement with the LC-MS/MS than those 
observed in ambulatory osteoporotic patients.
The most important limitation of this study is the 
relatively small number of subjects included in each sub-
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some situations of discrepancies, but our study has also 
some strengths, like the use of a VDSP-traceable LC-MS/
MS, re-validated on the Labquality panel, the ISO 15189 
accreditation of our laboratory and, of course, the impor-
tant sub-populations that we studied.
Finally, an important conclusion regarding the stand-
ardization of the assays can be drawn from this study. 
Indeed, our results show that the different immunoassays 
presented here are not far from being correctly “stand-
ardized” compared to our VDSP-traceable LC-MS/MS in a 
general healthy population. Having a correct “standardi-
zation” in diseased patients whom 25(OH)D is requested 
seems much more complicated and this should be the 
challenge of both manufacturers and VDSP consortium to 
achieve this goal.
In conclusion, the new sandwich assay for 25(OH)D 
determination provided by Fujirebio on the Lumipulse®G 
presents interesting analytical results and better clini-
cal results compared to classical competition assays, but 
we have to unfortunately acknowledge a poor concord-
ance of the immunoassays with LC-MS/MS in patients for 
whom the test is important. It is clear that the “vitamin 
D assays market” is now saturated, but efforts in improv-
ing the assays are mandatory and collaboration between 
IVD manufacturers and clinical laboratories is of highest 
importance to improve the assays.
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